Evaluation of the effect of intravesical transplantation of allogeneic mesenchymal stem cells on improving bladder voiding function in patients with neurogenic underactive bladder, a clinical trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241124063822N1

Enrollment

Registered

2026-01-06

Start date

2026-01-21

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

flaccid neurogenic bladder. Neuromuscular dysfunction of bladder, unspecified

Interventions

The intervention group: After receiving a complete explanation of the study, patients must provide written informed consent prior to intervention. Following patient selection, the study procedures wil

Eligibility

Sex/Gender

All

Age

30 Years to 75 Years

Inclusion criteria

Inclusion criteria: Detrusor underactivity diseases confirmed by the urodynamic study with known etiology 30-75-year-old patients with residual urine volume of more than 300 cc fullfillment of consent form

Exclusion criteria

Exclusion criteria: Any concurrent related comorbidities, such as recurrent UTI, malignancies, related surgical intervention within the past year, and renal and cardiac diseases patients' refusal of collaboration

Design outcomes

Primary

Measure	Time frame
Evaluation of post-void residue changes. Timepoint: Before the intervention and on day 90 after the intervention. Method of measurement: urodynamic study,.;Evaluation of maximal urine flow (Qmax) changes. Timepoint: before the intervention and on day 90 after the intervention. Method of measurement: urodynamic study,.;Evaluation of average urine flow (Qave) changes. Timepoint: Before the intervention and on day 90 after the intervention. Method of measurement: urodynamic study,.;Evaluation of maximum detrusor pressure changes. Timepoint: before the intervention, day 90 after the intervention. Method of measurement: urodynamic study,.;Evaluation of bladder contraction index (BCI) changes. Timepoint: before the intervention and on day 90 after the intervention. Method of measurement: urodynamic study,.;Evaluation of treatment effect on quality of life, and urinary symptoms. Timepoint: before the intervention and on days 90 and 180 after the intervention. Method of measurement: ICIQ-LUTS-QOL questionnaire.	—

Measure

Time frame

Evaluation of post-void residue changes. Timepoint: Before the intervention and on day 90 after the intervention. Method of measurement: urodynamic study,.;Evaluation of maximal urine flow (Qmax) changes. Timepoint: before the intervention and on day 90 after the intervention. Method of measurement: urodynamic study,.;Evaluation of average urine flow (Qave) changes. Timepoint: Before the intervention and on day 90 after the intervention. Method of measurement: urodynamic study,.;Evaluation of maximum detrusor pressure changes. Timepoint: before the intervention, day 90 after the intervention. Method of measurement: urodynamic study,.;Evaluation of bladder contraction index (BCI) changes. Timepoint: before the intervention and on day 90 after the intervention. Method of measurement: urodynamic study,.;Evaluation of treatment effect on quality of life, and urinary symptoms. Timepoint: before the intervention and on days 90 and 180 after the intervention. Method of measurement: ICIQ-LUTS-QOL questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSalman Soltani

Mashhad University of Medical Sciences

SoltaniS@mums.ac.ir+98 51 3854 3031

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026